Effects of coffee consumption in chronic hepatitis C: A randomized controlled trial
ABSTRACT BACKGROUND: Coffee is associated with a reduced risk of hepatocellular carcinoma in patients with chronic C hepatitis. This prospective trial was aimed at assessing the mechanisms underlying coffee-related protective effects. METHODS: Forty patients with chronic hepatitis C were randomized into two groups: the first consumed 4 cups of coffee/day for 30 days, while the second remained coffee "abstinent". At day 30, the groups were switched over for a second month. RESULTS: At baseline, aspartate aminotransferase and alanine aminotransferase were lower in patients drinking 3-5 (Group B) than 0-2 cups/day (Group A) (56±6 vs 74±11/60±3 vs 73±7U/L p=0.05/p=0.04, respectively). HCV-RNA levels were significantly higher in Group B [(6.2±1.5)×10(5)vs (3.9±1.0)×10(5)UI/mL, p=0.05]. During coffee intake, 8-hydroxydeoxyguanosine and collagen levels were significantly lower than during abstinence (15±3 vs 44±16 8-hydroxydeoxyguanosine/10(5)deoxyguanosine, p=0.05 and 56±9 vs 86±21ng/mL, p=0.04). Telomere length was significantly higher in patients during coffee intake (0.68±0.06 vs 0.48±0.04 Arbitrary Units, p=0.006). Telomere length and 8-hydroxydeoxyguanosine were inversely correlated. CONCLUSION: In chronic hepatitis C coffee consumption induces a reduction in oxidative damage, correlated with increased telomere length and apoptosis, with lower collagen synthesis, factors that probably mediate the protection exerted by coffee with respect to disease progression.
Article: Coffee, chronic diseases and cancerEuropean journal of clinical nutrition 06/2013; 67(8). DOI:10.1038/ejcn.2013.111 · 2.95 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: After exposure to the hepatitis C virus (HCV) only a minority of patients will resolve the infection spontaneously, and the prognosis of these patients is excellent. Patients with chronic HCV infection may develop hepatic fibrosis and can experience symptoms, although these remain largely non-specific up to the point cirrhosis has established. At the stage of cirrhosis, liver failure and hepatocellular carcinoma are the most important causes of the increased mortality. The rate of disease progression varies considerably among patients, and has been associated with several host and virus-related factors. Assessment of the patient’s individual risk for disease progression is relevant for guidance and clinical decision making, especially with all upcoming antiviral treatment improvements. Importantly, successful antiviral therapy has shown great potential to prevent chronification among patients with acute HCV infection as well as to prevent cirrhosis-related morbidity and mortality among those patients with chronic HCV infection.Current Hepatitis Reports 12/2013; 12(4):251-260. DOI:10.1007/s11901-013-0195-1
- Alimentary Pharmacology & Therapeutics 03/2014; 39(6):643. DOI:10.1111/apt.12637 · 4.55 Impact Factor